Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Glenmark receives USFDA approval for telmisartan tablets

Telmisartan, which is the generic version of Boehringer Ingelheim's Micardis, garnered annual sales of $ 250 million for the 12 month period ending March 2014

BS B2B Bureau  |  Mumbai 

Glenmark Generics Inc, the US-based subsidiary of Glenmark Generics Limited, has been granted final abbreviated new drug approval (ANDA) from the US Food and Drug Administration (USFDA) for telmisartan tablets in the strength of 20 mg, 40 mg and 80 mg. Following the approval, Glenmark will commence distribution of the product immediately.
 
Telmisartan tablets are Glenmark’s generic version of Boehringer Ingelheim’s Micardis. For the 12 month period ending March 2014, telmisartan, which is indicated for the treatment of hypertension, garnered annual sales of $ 250 million, according to IMS Health.
 
Glenmark’s current portfolio consists of 92 products authorised for distribution in the US marketplace and 73 ANDA’s pending approval with the USFDA.

First Published: Wed, July 09 2014. 13:33 IST
RECOMMENDED FOR YOU

Glenmark receives USFDA approval for telmisartan tablets

Telmisartan, which is the generic version of Boehringer Ingelheim's Micardis, garnered annual sales of $ 250 million for the 12 month period ending March 2014

Telmisartan, which is the generic version of Boehringer Ingelheim's Micardis, garnered annual sales of $ 250 million for the 12 month period ending March 2014 Glenmark Generics Inc, the US-based subsidiary of Glenmark Generics Limited, has been granted final abbreviated new drug approval (ANDA) from the US Food and Drug Administration (USFDA) for telmisartan tablets in the strength of 20 mg, 40 mg and 80 mg. Following the approval, Glenmark will commence distribution of the product immediately.
 
Telmisartan tablets are Glenmark’s generic version of Boehringer Ingelheim’s Micardis. For the 12 month period ending March 2014, telmisartan, which is indicated for the treatment of hypertension, garnered annual sales of $ 250 million, according to IMS Health.
 
Glenmark’s current portfolio consists of 92 products authorised for distribution in the US marketplace and 73 ANDA’s pending approval with the USFDA.
image
Business Standard
177 22

Glenmark receives USFDA approval for telmisartan tablets

Telmisartan, which is the generic version of Boehringer Ingelheim's Micardis, garnered annual sales of $ 250 million for the 12 month period ending March 2014

Glenmark Generics Inc, the US-based subsidiary of Glenmark Generics Limited, has been granted final abbreviated new drug approval (ANDA) from the US Food and Drug Administration (USFDA) for telmisartan tablets in the strength of 20 mg, 40 mg and 80 mg. Following the approval, Glenmark will commence distribution of the product immediately.
 
Telmisartan tablets are Glenmark’s generic version of Boehringer Ingelheim’s Micardis. For the 12 month period ending March 2014, telmisartan, which is indicated for the treatment of hypertension, garnered annual sales of $ 250 million, according to IMS Health.
 
Glenmark’s current portfolio consists of 92 products authorised for distribution in the US marketplace and 73 ANDA’s pending approval with the USFDA.

image
Business Standard
177 22